JP2001502303A - 腸細胞発現による治療用遺伝子産生物の送達 - Google Patents

腸細胞発現による治療用遺伝子産生物の送達

Info

Publication number
JP2001502303A
JP2001502303A JP10514853A JP51485398A JP2001502303A JP 2001502303 A JP2001502303 A JP 2001502303A JP 10514853 A JP10514853 A JP 10514853A JP 51485398 A JP51485398 A JP 51485398A JP 2001502303 A JP2001502303 A JP 2001502303A
Authority
JP
Japan
Prior art keywords
protein
cells
dna
intestinal
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP10514853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001502303A5 (enExample
Inventor
ジャーマン、マイケル
ゴールドファイン、アイラ、ディー．
ロスマン、スティーヴン、エス．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2001502303A publication Critical patent/JP2001502303A/ja
Publication of JP2001502303A5 publication Critical patent/JP2001502303A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP10514853A 1996-09-19 1997-09-18 腸細胞発現による治療用遺伝子産生物の送達 Ceased JP2001502303A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/717,084 1996-09-19
US08/717,084 US6225290B1 (en) 1996-09-19 1996-09-19 Systemic gene therapy by intestinal cell transformation
PCT/US1997/016523 WO1998011779A1 (en) 1996-09-19 1997-09-18 Delivery of therapeutic gene products by intestinal cell expression

Publications (2)

Publication Number Publication Date
JP2001502303A true JP2001502303A (ja) 2001-02-20
JP2001502303A5 JP2001502303A5 (enExample) 2005-05-12

Family

ID=24880656

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10514853A Ceased JP2001502303A (ja) 1996-09-19 1997-09-18 腸細胞発現による治療用遺伝子産生物の送達

Country Status (10)

Country Link
US (4) US6225290B1 (enExample)
EP (1) EP0939590B1 (enExample)
JP (1) JP2001502303A (enExample)
AT (1) ATE320186T1 (enExample)
AU (1) AU729457B2 (enExample)
CA (1) CA2264744A1 (enExample)
DE (1) DE69735496T2 (enExample)
DK (1) DK0939590T3 (enExample)
ES (1) ES2256896T3 (enExample)
WO (1) WO1998011779A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US7749215B1 (en) * 1998-02-05 2010-07-06 Biosense, Inc. Intracardiac cell delivery and cell transplantation
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
CA2323776C (en) 1998-03-19 2010-04-27 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
NZ506648A (en) * 1998-03-20 2003-08-29 Benitec Australia Ltd Control of gene expression through introduction of synthetic tandem repeats to reduce translation of mRNA
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
PL345241A1 (en) * 1998-05-06 2001-12-03 Upjohn Co Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate
JPH11335269A (ja) 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
AU777988B2 (en) * 1999-02-19 2004-11-11 Engene, Inc. Peroral gene therapy of diabetes and obesity
EP1889914A1 (en) * 1999-02-19 2008-02-20 Engene, Inc. Compositions for gene therapy of diabetes
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
NZ514620A (en) * 1999-03-04 2004-04-30 Ppl Therapeutics Scotland Ltd Genetic modification of somatic cells and uses thereof
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US6953658B2 (en) 2000-03-09 2005-10-11 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
CN102151337B (zh) 2000-03-13 2014-03-12 恩根尼公司 调节消化道蛋白表达的组合物和方法
DK2796553T3 (da) * 2000-03-30 2019-09-30 Whitehead Inst Biomedical Res Rna-sekvensspecifikke formidlere af rna-interferens
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
GB0010630D0 (en) * 2000-05-04 2000-06-21 Univ Wales Medicine Sequence
EP1294949A4 (en) 2000-06-15 2004-08-25 Human Genome Sciences Inc HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
US6774223B2 (en) 2000-06-28 2004-08-10 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
CZ302719B6 (cs) 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
US20020151068A1 (en) * 2001-01-03 2002-10-17 Board Of Regents, The University Of Texas System Compositions and methods for the diagnosis and treatment of organophosphate toxicity
CA2437811A1 (en) 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
EP1383929A4 (en) * 2001-04-04 2006-06-07 Neurome Inc GENES EXPRESSED IN DARMEPITHELIAL CELLS AND PEYERS 'PATCH M-CELLS
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
AU2002311777A1 (en) * 2001-04-17 2002-10-28 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
WO2002094871A1 (en) * 2001-05-24 2002-11-28 Human Dna Technology Inc Novel keratinocyte growth factor-2 analogue in hair follicle
AU2002365188A1 (en) * 2001-11-07 2003-07-30 Musc Foundation For Research Development Nucleic acid delivery and expression
US20030135195A1 (en) * 2002-01-16 2003-07-17 Oscar Jimenez Highly lubricious hydrophilic coating utilizing dendrimers
AU2003215272B2 (en) 2002-02-14 2008-04-03 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
WO2003104439A2 (en) * 2002-03-12 2003-12-18 Surface Logix, Inc. Assay device that analyzes the absorption, metabolism, permeability and/or toxicity of a candidate compound
US7374930B2 (en) * 2002-05-21 2008-05-20 Expression Genetics, Inc. GLP-1 gene delivery for the treatment of type 2 diabetes
AU2003273206B2 (en) * 2002-05-31 2009-08-20 Children's Hospital Medical Center Method, composition and kit for antigenic binding of Norwalk-Like viruses
US7977098B2 (en) 2002-05-31 2011-07-12 Children's Hospital Medical Center Antigenic binding patterns of norovirus to human histo-blood group antigens
US20040014704A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent induces tolerance
US20040016013A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20070031920A1 (en) * 2002-10-24 2007-02-08 Biogen, Inc. High expression locus vector based on ferritin heavy chain gene locus
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
WO2005032574A1 (en) * 2003-10-03 2005-04-14 The Board Of Trustees Of The Leland Stanford Junior University Modulation of gastrointestinal epithelium proliferation through the wnt signaling pathway
US20050208032A1 (en) * 2004-01-16 2005-09-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
JP2009519983A (ja) * 2005-12-20 2009-05-21 アラーナ・テラピューティクス・リミテッド 部分的な新世界ザル結合領域を有するキメラ抗体
CN105853394A (zh) * 2006-03-30 2016-08-17 恩根尼公司 用于体内转染肠细胞的非病毒组合物和方法
JP2011504366A (ja) * 2007-11-26 2011-02-10 プラント バイオサイエンス リミティド エンドリシン活性を有する新規ポリペプチド及びその使用
US8703152B2 (en) 2008-06-03 2014-04-22 University Of Rochester Methods of treating inflammatory intestinal disease and managing symptoms thereof
US20100069887A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Multiple chamber ex vivo adjustable-release final dosage form
US20100068152A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable particle or polymeric based final dosage form
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US20100068278A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liablity Corporation Of The State Of Delaware Ex vivo modifiable medicament release-associations
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
GB0908949D0 (en) 2009-05-26 2009-07-01 Plant Bioscience Ltd Novel polypeptides having endolysin activity and uses thereof
CN107043408B (zh) 2009-06-09 2021-02-09 儿童医院医疗中心 抗原-诺罗病毒p-结构域单体和二聚体，抗原-诺罗病毒p-粒子分子，及其制备和应用方法
US9321803B2 (en) 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
RU2736495C2 (ru) 2014-04-01 2020-11-17 Рубиус Терапьютикс, Инк. Способ и композиции для иммуномодуляции
US20160160229A1 (en) * 2014-12-09 2016-06-09 THC Farmaceuticals, Inc. Methods of producing antibody-rich cannabis and honeysuckle plants
CA3053522A1 (en) 2017-03-28 2018-10-04 Children's Hospital Medical Center Norovirus s particle based vaccines and methods of making and using same
US20230023615A1 (en) * 2019-12-13 2023-01-26 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
KR20220142432A (ko) * 2019-12-20 2022-10-21 트랜슬레이트 바이오 인코포레이티드 메신저 rna의 직장 전달

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643579A (en) * 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
JPH04504950A (ja) 1988-11-23 1992-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 位置特異的挿入ベクターおよびこれを用いた方法
DE69034168T3 (de) 1989-03-21 2013-04-11 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
WO1991006309A1 (en) 1989-11-03 1991-05-16 Vanderbilt University Method of in vivo delivery of functioning foreign genes
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
AU3972893A (en) * 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
CA2153068C (en) * 1992-12-31 2007-05-01 Donald Kufe Enhancer sequence for modulating expression in epithelial cells
SG54115A1 (en) 1993-04-27 1998-11-16 Gerber Scient Products Inc Thermal printing apparatus with improved power supply
JPH08511423A (ja) 1993-06-10 1996-12-03 ジェネティック セラピー，インコーポレイテッド 血友病治療のためのアデノウイルスベクター
US5681744A (en) * 1995-03-17 1997-10-28 Greenstein; Robert J. Delivery and expression of heterologus genes using upstream enhancer regions of mammalian gene promoters
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
AU6097896A (en) 1995-06-07 1996-12-30 Alza Corporation Oral delivery of gene constructs
US6248720B1 (en) * 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation

Also Published As

Publication number Publication date
WO1998011779A1 (en) 1998-03-26
EP0939590A4 (en) 2002-09-04
US6258789B1 (en) 2001-07-10
US20020039574A1 (en) 2002-04-04
DE69735496T2 (de) 2006-09-21
US20050026863A1 (en) 2005-02-03
US6831070B2 (en) 2004-12-14
EP0939590A1 (en) 1999-09-08
EP0939590B1 (en) 2006-03-15
CA2264744A1 (en) 1998-03-26
US6225290B1 (en) 2001-05-01
ATE320186T1 (de) 2006-04-15
DK0939590T3 (da) 2006-07-24
AU729457B2 (en) 2001-02-01
AU4422197A (en) 1998-04-14
DE69735496D1 (de) 2006-05-11
ES2256896T3 (es) 2006-07-16

Similar Documents

Publication Publication Date Title
JP2001502303A (ja) 腸細胞発現による治療用遺伝子産生物の送達
CN102037008B (zh) 蛋白酶稳定化的、酰化胰岛素类似物
JP2828250B2 (ja) 真性糖尿病の治療
JP5902679B2 (ja) ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
EP2081958B1 (en) Peptide extended insulins
JP5475836B2 (ja) 新規インシュリン誘導体
US10626156B2 (en) Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
CA2216149A1 (en) Gene therapy by secretory gland expression
JP2002512612A (ja) 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法
US8653022B2 (en) Use of ghrelin splice variant for treating hypercholesterolemia and/or high cholesterol and/or high cholesterol complication and/or lipemia and/or lipemia complication and/or coronary heart disease and/or weight management and/or diabetes and/or hyperglycemia
US6780846B1 (en) Membrane translocating peptide drug delivery system
CA2386231C (en) Membrane translocating peptide drug delivery system
AU744279B2 (en) Protein delivery by secretory gland expression
US9238010B2 (en) Vesicles and nanostructures from recombinant proteins
JP2009516711A (ja) 糖尿病の処置のための組成物および方法
US10660941B2 (en) Orally administrable pharmaceutical preparation containing protein
CN101321780A (zh) 胰岛素受体拮抗剂及相关组合物、用途和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080225

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20080610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080722